| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0091270008328098 |
| P8608 | Fatcat ID | release_ntpmk2g77nandmqzlr4bl5u23e |
| P698 | PubMed publication ID | 19179293 |
| P2093 | author name string | Shiew-Mei Huang | |
| Urs A Meyer | |||
| Atiqur Rahman | |||
| Lawrence J Lesko | |||
| Myong-Jin Kim | |||
| P2860 | cites work | Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation | Q28210235 |
| Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34012421 | ||
| CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis | Q34394876 | ||
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose | Q34417386 | ||
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose | Q34423204 | ||
| National surveillance of emergency department visits for outpatient adverse drug events | Q34574654 | ||
| Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action | Q34647850 | ||
| Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors | Q35806446 | ||
| Genetic-based dosing in orthopedic patients beginning warfarin therapy. | Q35989429 | ||
| Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests | Q36336291 | ||
| Pharmacogenetics of target genes across the warfarin pharmacological pathway | Q36656419 | ||
| Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans | Q36882317 | ||
| Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues | Q36956360 | ||
| A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding | Q37087333 | ||
| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin | Q37196787 | ||
| The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics | Q37247571 | ||
| CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. | Q40174813 | ||
| Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting | Q43793456 | ||
| Major bleeding caused by warfarin in a genetically susceptible patient | Q43856655 | ||
| Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy | Q43942672 | ||
| Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial | Q44054411 | ||
| Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity | Q44680862 | ||
| Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin | Q44787224 | ||
| A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. | Q45052744 | ||
| Warfarin and pharmacogenomic testing: the case for restraint | Q46421340 | ||
| Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose | Q46433362 | ||
| The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen | Q46537717 | ||
| Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes | Q46816940 | ||
| The risk of hemorrhage among patients with warfarin-associated coagulopathy | Q46951753 | ||
| A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. | Q51932266 | ||
| Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. | Q53248119 | ||
| Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. | Q53257773 | ||
| P433 | issue | 2 | |
| P921 | main subject | (RS)-warfarin | Q407431 |
| P304 | page(s) | 138-146 | |
| P577 | publication date | 2009-02-01 | |
| P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
| P1476 | title | A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity | |
| P478 | volume | 49 |
| Q43089518 | A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. |
| Q33846255 | Applied pharmacogenomics in cardiovascular medicine |
| Q51071834 | Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. |
| Q47584698 | Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat |
| Q35032378 | Clinically relevant genetic variations in drug metabolizing enzymes |
| Q37358362 | Evaluation of education on the appropriate use of vitamin k in warfarin reversal in adult inpatients |
| Q84265482 | Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypes |
| Q49142379 | Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. |
| Q36015458 | Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin |
| Q38239244 | Oral anticoagulants and status of antidotes for the reversal of bleeding risk. |
| Q38100809 | Personalized diagnostics and biosensors: a review of the biology and technology needed for personalized medicine |
| Q37142852 | Personalized vascular medicine: individualizing drug therapy |
| Q37828165 | Pharmacoeconomic evaluation of warfarin pharmacogenomics. |
| Q84523980 | Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiation |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q94410300 | Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing |
| Q44703823 | Rapid and cost-effective SNP detection method: application of SmartAmp2 to pharmacogenomics research |
| Q46673228 | Rationalized DNA sequencing-based protocol for genotyping patients receiving coumarin therapy |
| Q33447738 | Riociguat (BAY 63–2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study |
| Q51622508 | VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. |
| Q31131437 | Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model |
| Q55652414 | Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. |
| Q39862947 | Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. |
Search more.